Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Resmed (RSMDF) Current Leases (2019 - 2025)

Historic Current Leases for Resmed (RSMDF) over the last 7 years, with Q4 2025 value amounting to $29.8 million.

  • Resmed's Current Leases rose 700.06% to $29.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.8 million, marking a year-over-year increase of 700.06%. This contributed to the annual value of $30.5 million for FY2025, which is 2068.2% up from last year.
  • Latest data reveals that Resmed reported Current Leases of $29.8 million as of Q4 2025, which was up 700.06% from $30.0 million recorded in Q3 2025.
  • Resmed's Current Leases' 5-year high stood at $30.5 million during Q2 2025, with a 5-year trough of $21.1 million in Q3 2022.
  • Its 5-year average for Current Leases is $24.9 million, with a median of $24.0 million in 2021.
  • In the last 5 years, Resmed's Current Leases tumbled by 804.14% in 2022 and then soared by 2974.54% in 2024.
  • Resmed's Current Leases (Quarter) stood at $23.9 million in 2021, then dropped by 6.2% to $22.4 million in 2022, then grew by 7.26% to $24.1 million in 2023, then grew by 15.61% to $27.8 million in 2024, then grew by 7.0% to $29.8 million in 2025.
  • Its Current Leases stands at $29.8 million for Q4 2025, versus $30.0 million for Q3 2025 and $30.5 million for Q2 2025.